Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·Why the medicine matters when watching for side effects in children with cancer
Review or Meta-AnalysisA review found pain and fever often reported with dinutuximab, while chemotherapy combinations and uneven toxicity reporting make drug comparisons uncertain.
-
Evidence date ·What did early COVID-19 studies find about cancer treatments and death?
Review or Meta-AnalysisA review of 16 studies linked active chemotherapy to higher odds of death in cancer patients with COVID-19; no clear link emerged for four other treatment categories.
-
Evidence date ·Why might a tiny drug carrier matter in cervical cancer care?
Review or Meta-AnalysisA 2021 review considers nanocellulose as a carrier for different cancer drugs and asks whether delivery design could make cervical cancer treatment gentler.
-
Evidence date ·What else matters when a nanoparticle reaches a tumour?
Review or Meta-AnalysisA 2021 review explains how tumour genetics, gut microbes, sex and age shape the immune setting in which nanoparticle cancer treatments are tested.
-
Evidence date ·Why pair immune checkpoint drugs with nanoparticles?
Review or Meta-AnalysisImmune checkpoint drugs help immune cells attack cancer but can cause serious adverse events. A 2021 review asks whether nanoparticles could carry them toward tumors.
-
Evidence date ·CAR-T treatment must target cancer and limit harm
Review or Meta-AnalysisA 2021 review considers CAR-T therapy in blood cancers and solid tumors, and proposes combined approaches to improve tumor control while limiting adverse effects.
-
Evidence date ·What did a 2021 review find about liver cancer treatment?
Review or Meta-AnalysisA review examined 23 published liver cancer trials and two trial abstracts. Few drugs tested after sorafenib proved effective, while immunotherapy was emerging.
-
Evidence date ·Why has an immune-cell activation signal been hard to turn into cancer treatment?
Review or Meta-AnalysisTracked over timeA 2026 review explains why the T cell carrying OX40 matters and why limited responses to drugs used alone are driving research into combinations.
-
Evidence date ·What does an OX40 immune boost need around it to help fight a tumor?
Review or Meta-AnalysisTracked over timeEarly OX40 combinations added little to checkpoint treatment in patients. A 2023 review examines timing, tumor recognition and drug design as possible reasons.
-
Evidence date ·What a patent review shows about OX40 cancer drug development
Review or Meta-AnalysisTracked over timeThe review reports rising OX40 agonist patent activity, especially in 2018 and 2019, and says six candidates represented 68% of related trials.